Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23487300 | 0.95 | STS (0.35) | STSABCG2FFAR4GABRA1GABRG2 | |
| SCHEMBL22563536 | 0.94 | STS (0.34) | STSCYP11B1CYP11B2ABCG2PRMT5 | |
| SCHEMBL22268552 | 0.93 | STS (0.36) | STSCYP11B1CYP11B2ABCG2PRMT5 | |
| SCHEMBL19943170 | 0.91 | STS (0.36) | STSCYP11B1CYP11B2PRMT5WDR77 | |
| SCHEMBL23487701 | 0.91 | CHEK1 (0.39) | CYP11B2ABCG2CHEK1 | |
| SCHEMBL22563696 | 0.91 | SCARB1 (0.35) | CYP11B1CYP11B2ABCG2SCARB1GRM5 | |
| SCHEMBL19909049 | 0.90 | STS (0.36) | STSCYP11B1CYP11B2PRMT5WDR77 | |
| SCHEMBL23487696 | 0.90 | STS (0.34) | STSABCG2FFAR4GABRA1GABRG2 | |
| SCHEMBL22563522 | 0.89 | STS (0.34) | STSCYP11B1CYP11B2ABCG2PRMT5 | |
| SCHEMBL22268551 | 0.89 | STS (0.35) | STSABCG2FFAR4GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210175434-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-06-10 | — | — | US | disclosed |
| EP-3580300-B1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210175434-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | OR10J3, OR51E2, OCIAD2 | STS 3725/4885CYP11B1 1451/4885CYP11B2 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.